UBS analyst Trung Huynh lowered the firm’s price target on Amgen (AMGN) to $315 from $319 and keeps a Neutral rating on the shares. The firm notes a “strong” operational start to the year, but believes the investment in the pipeline growth tempers margin expansion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: